SGMO RSI Chart
Last 7 days
14.3%
Last 30 days
23.1%
Last 90 days
-53.6%
Trailing 12 Months
-50.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 241.0M | 218.5M | 201.4M | 176.2M |
2022 | 112.7M | 114.2M | 112.1M | 111.3M |
2021 | 131.4M | 137.7M | 108.5M | 110.7M |
2020 | 107.4M | 111.4M | 147.2M | 118.2M |
2019 | 79.9M | 76.0M | 74.4M | 102.4M |
2018 | 45.8M | 58.9M | 70.7M | 84.5M |
2017 | 18.9M | 23.4M | 32.4M | 36.6M |
2016 | 30.0M | 25.3M | 19.6M | 19.4M |
2015 | 51.2M | 49.2M | 45.4M | 39.5M |
2014 | 27.6M | 31.1M | 37.8M | 45.9M |
2013 | 23.0M | 25.4M | 26.2M | 24.1M |
2012 | 11.4M | 14.4M | 17.5M | 21.7M |
2011 | 16.4M | 11.3M | 10.3M | 10.3M |
2010 | 0 | 21.7M | 21.3M | 20.8M |
2009 | 0 | 0 | 0 | 22.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 25, 2024 | duraibabu prathyusha | sold (taxes) | -3,901 | 1.13 | -3,453 | svp, chief financial officer |
Feb 25, 2024 | pooler amy | sold (taxes) | -2,778 | 1.13 | -2,459 | vp, head of research |
Feb 25, 2024 | macrae sandy | sold (taxes) | -27,297 | 1.13 | -24,157 | president, ceo and director |
Feb 25, 2024 | willoughby scott b. | sold (taxes) | -3,901 | 1.13 | -3,453 | svp, gen. counsel & secretary |
Feb 25, 2024 | dubois-stringfellow nathalie | sold (taxes) | -5,661 | 1.13 | -5,010 | svp-chief development officer |
Feb 24, 2024 | willoughby scott b. | sold (taxes) | -4,948 | 1.13 | -4,379 | svp, gen. counsel & secretary |
Feb 24, 2024 | macrae sandy | sold (taxes) | -18,209 | 1.13 | -16,115 | president, ceo and director |
Feb 24, 2024 | dubois-stringfellow nathalie | sold (taxes) | -6,185 | 1.13 | -5,474 | svp-chief development officer |
Feb 24, 2024 | pooler amy | sold (taxes) | -2,496 | 1.13 | -2,209 | vp, head of research |
Feb 24, 2024 | duraibabu prathyusha | sold (taxes) | -6,185 | 1.13 | -5,474 | svp, chief financial officer |
Which funds bought or sold SGMO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | 3,173 | 16,755 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.92 | -3,284 | 10,038 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -74.98 | -51,850 | 23,146 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -89.39 | -27,000 | 5,000 | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 247,059 | 247,059 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | reduced | -80.96 | -419,036 | 128,644 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -1.58 | 130,581 | 740,489 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -24.64 | -11,289 | 148,985 | -% |
May 15, 2024 | AQR CAPITAL MANAGEMENT LLC | new | - | 20,359 | 20,359 | -% |
May 15, 2024 | D. E. Shaw & Co., Inc. | reduced | -34.51 | -489,007 | 2,055,800 | -% |
Unveiling Sangamo Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Sangamo Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Sangamo Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -100.0% | - | 2,042,000 | 9,398,000 | 6,835,000 | 157,957,000 | 27,230,000 | 26,460,000 | 29,378,000 | 28,231,000 | 27,986,000 | 28,563,000 | 27,872,000 | 26,280,000 | 25,800,000 | 57,763,000 | 21,553,000 | 13,076,000 | 54,851,000 | 21,958,000 | 17,548,000 | 8,071,000 |
Operating Expenses | -18.9% | 52,007,000 | 64,101,000 | 115,806,000 | 130,407,000 | 139,923,000 | 82,622,000 | 81,354,000 | 75,112,000 | 73,492,000 | 67,885,000 | 76,999,000 | 76,572,000 | 72,582,000 | 69,232,000 | 61,464,000 | 59,450,000 | 57,598,000 | 53,382,000 | 51,206,000 | 51,052,000 | 51,968,000 |
S&GA Expenses | -100.0% | - | 13,099,000 | 13,918,000 | 16,014,000 | 18,136,000 | 16,443,000 | 16,238,000 | 15,093,000 | 14,908,000 | 16,084,000 | 14,501,000 | 16,486,000 | 16,148,000 | 16,874,000 | 16,177,000 | 17,927,000 | 16,119,000 | 15,053,000 | 14,918,000 | 14,597,000 | 17,118,000 |
R&D Expenses | -29.2% | 35,891,000 | 50,706,000 | 57,089,000 | 63,046,000 | 63,216,000 | 66,179,000 | 65,116,000 | 60,019,000 | 58,584,000 | 51,801,000 | 62,498,000 | 60,086,000 | 56,434,000 | 52,358,000 | 45,287,000 | 41,523,000 | 41,479,000 | 38,329,000 | 36,288,000 | 36,455,000 | 34,850,000 |
EBITDA Margin | -29.2% | -1.82 | -1.41 | -1.18 | -0.87 | -0.47 | -1.61 | -1.49 | -1.46 | -1.49 | -1.52 | -1.04 | -0.82 | - | - | - | - | - | - | - | - | - |
Income Taxes | 136.0% | 98,000 | -272,000 | 1,270,000 | -6,264,000 | 194,000 | 238,000 | 30,000 | 82,000 | 100,000 | -73,500 | 100,000 | 24,000 | 262,000 | 108,000 | 237,000 | - | - | - | - | - | - |
Earnings Before Taxes | 19.1% | -48,991,000 | -60,567,000 | -102,893,000 | -120,770,000 | 21,327,000 | -51,714,000 | -53,125,000 | -43,091,000 | -43,919,000 | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -26.7% | -1.89 | -1.49 | -1.26 | -0.94 | -0.53 | -1.72 | -1.59 | -1.56 | -1.58 | -1.61 | -1.11 | -0.88 | - | - | - | - | - | - | - | - | - |
Net Income | 18.6% | -49,089,000 | -60,295,000 | -104,163,000 | -114,506,000 | 21,133,000 | -51,973,000 | -53,155,000 | -43,173,000 | -43,977,000 | -37,488,000 | -47,688,000 | -47,174,000 | -45,933,000 | -40,604,000 | -1,550,000 | -35,929,000 | -42,913,000 | 4,555,000 | -27,307,000 | -30,284,000 | -42,150,000 |
Net Income Margin | -27.2% | -1.86 | -1.46 | -1.24 | -0.91 | -0.53 | -1.73 | -1.59 | -1.51 | -1.57 | -1.61 | -1.67 | -0.98 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 8.5% | -48,663,000 | -53,209,000 | -50,037,000 | -66,251,000 | -76,500,000 | -64,523,000 | -58,031,000 | -59,430,000 | -61,814,000 | -55,572,000 | -64,627,000 | -59,830,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -22.0% | 129 | 165 | 220 | 325 | 441 | 563 | 594 | 617 | 654 | 722 | 772 | 835 | 877 | 939 | 964 | 895 | 584 | 638 | 640 | 673 | 543 |
Current Assets | -27.2% | 69.00 | 94.00 | 148 | 160 | 227 | 300 | 337 | 343 | 340 | 399 | 447 | 554 | 607 | 660 | 700 | 679 | 371 | 405 | 384 | 462 | 363 |
Cash Equivalents | 22.4% | 55.00 | 45.00 | 57.00 | 67.00 | 78.00 | 100 | 95.00 | 118 | 120 | 180 | 177 | 170 | 123 | 133 | 259 | 467 | 86.00 | 82.00 | 114 | 169 | 81.00 |
Net PPE | -18.1% | 22.00 | 27.00 | 28.00 | 61.00 | 60.00 | 64.00 | 56.00 | 53.00 | 52.00 | 52.00 | 51.00 | 50.00 | 45.00 | 41.00 | 35.00 | 34.00 | 31.00 | 30.00 | 27.00 | 21.00 | 18.00 |
Goodwill | - | - | - | - | - | - | 38.00 | 35.00 | 37.00 | 39.00 | 40.00 | 41.00 | 42.00 | 41.00 | 43.00 | 41.00 | 39.00 | 39.00 | 39.00 | 38.00 | 40.00 | 39.00 |
Liabilities | -12.3% | 72.00 | 82.00 | 85.00 | 91.00 | 105 | 268 | 285 | 299 | 320 | 347 | 366 | 390 | 408 | 441 | 443 | 383 | 190 | 205 | 221 | 228 | 214 |
Current Liabilities | -15.7% | 40.00 | 48.00 | 48.00 | 54.00 | 58.00 | 112 | 122 | 120 | 119 | 128 | 132 | 137 | 133 | 144 | 124 | 94.00 | 62.00 | 70.00 | 81.00 | 82.00 | 91.00 |
Shareholder's Equity | -31.6% | 57.00 | 83.00 | 135 | 234 | 336 | 295 | 309 | 318 | 335 | 375 | 406 | 445 | 469 | 497 | 521 | 511 | 394 | 433 | 419 | 446 | 329 |
Retained Earnings | -3.5% | -1,455 | -1,406 | -1,346 | -1,241 | -1,127 | -1,148 | -1,096 | -1,043 | -1,000 | -956 | -918 | -871 | -823 | -777 | -737 | -735 | -699 | -656 | -661 | -634 | -603 |
Additional Paid-In Capital | 1.6% | 1,516 | 1,492 | 1,486 | 1,480 | 1,467 | 1,450 | 1,423 | 1,373 | 1,340 | 1,334 | 1,324 | 1,313 | 1,292 | 1,269 | 1,256 | 1,248 | 1,097 | 1,091 | 1,084 | 1,079 | 934 |
Shares Outstanding | 1.2% | 180 | 178 | 177 | 174 | 169 | 167 | 151 | 147 | 146 | 145 | 145 | 144 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.94 | -0.87 | -0.53 | -0.25 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 |
Float | - | - | - | - | 229 | - | - | - | 633 | - | - | - | 1,734 | - | - | - | 1,262 | - | - | - | 1,245 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 3.7% | -48,663 | -50,538 | -47,293 | -60,711 | -66,300 | -57,049 | -53,618 | -53,985 | -58,975 | -52,714 | -59,420 | -52,567 | -68,550 | -4,295 | 33,067 | 159,993 | -18,890 | -20,816 | -38,874 | -39,593 | -45,119 |
Share Based Compensation | -55.5% | 2,719 | 6,107 | 6,189 | 6,790 | 8,277 | 8,248 | 7,793 | 7,918 | 7,691 | 8,076 | 7,873 | 9,483 | 7,524 | 6,642 | 6,682 | 6,764 | 5,620 | 5,239 | 4,701 | 4,867 | 4,523 |
Cashflow From Investing | -5.0% | 35,840 | 37,708 | 37,627 | 42,468 | 35,728 | 42,613 | -13,462 | 28,429 | 1,705 | 52,635 | 60,976 | 89,299 | 45,289 | -130,458 | -242,497 | 77,608 | 23,720 | -16,402 | -16,217 | -12,383 | -14,799 |
Cashflow From Financing | 13146.7% | 22,122 | 167 | -100 | 6,519 | 8,002 | 19,535 | 43,818 | 22,874 | -1,567 | 2,112 | 5,492 | 10,019 | 15,235 | 6,919 | 1,616 | 144,156 | 409 | 1,219 | 704 | 139,890 | 216 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Revenues | $ 481 | $ 157,957 |
Operating expenses: | ||
Research and development | 35,891 | 63,216 |
General and administrative | 11,767 | 18,136 |
Impairment of long-lived assets | 4,349 | 20,433 |
Impairment of goodwill | 0 | 38,138 |
Total operating expenses | 52,007 | 139,923 |
(Loss) income from operations | (51,526) | 18,034 |
Interest and other income, net | 2,535 | 3,293 |
(Loss) income before income taxes | (48,991) | 21,327 |
Income tax expense | 98 | 194 |
Net (loss) income | $ (49,089) | $ 21,133 |
Net (loss) income per share | ||
Basic (in dollars per share) | $ (0.27) | $ 0.13 |
Diluted (in dollars per share) | $ (0.27) | $ 0.12 |
Shares used in computing net (loss) income per share | ||
Basic (in shares) | 180,342 | 168,533 |
Diluted (in shares) | 180,342 | 169,181 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 54,417 | $ 45,204 |
Restricted cash | 916 | 0 |
Marketable securities | 0 | 35,798 |
Accounts receivable | 691 | 923 |
Prepaid expenses and other current assets | 12,612 | 12,403 |
Total current assets | 68,636 | 94,328 |
Property and equipment, net | 22,017 | 26,874 |
Operating lease right-of-use assets | 20,935 | 25,991 |
Refundable research income tax credits and other non-current assets | 17,373 | 16,627 |
Restricted cash | 0 | 1,500 |
Total assets | 128,961 | 165,320 |
Current liabilities: | ||
Accounts payable | 15,468 | 15,259 |
Accrued compensation and employee benefits | 6,300 | 8,918 |
Other accrued liabilities | 18,474 | 23,554 |
Total current liabilities | 40,242 | 47,731 |
Long-term portion of lease liabilities | 30,817 | 33,515 |
Other non-current liabilities | 1,205 | 1,187 |
Total liabilities | 72,264 | 82,433 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,037 | 1,781 |
Additional paid-in capital | 1,515,926 | 1,492,077 |
Accumulated deficit | (1,455,465) | (1,406,376) |
Accumulated other comprehensive loss | (5,801) | (4,595) |
Total stockholders’ equity | 56,697 | 82,887 |
Total liabilities and stockholders’ equity | $ 128,961 | $ 165,320 |